<DOC>
	<DOC>NCT00053638</DOC>
	<brief_summary>This is a 48-week study to evaluate the safety and efficacy of a new tablet formulation containing two FDA-approved drugs in HIV-infected patients who have not received prior therapy. This tablet will be taken with one of two FDA-approved drugs as a once-daily regimen. Study physicians will evaluate subjects to determine if they have certain medical conditions, laboratory test values, medication use, or drug allergies that would exclude them from the study.</brief_summary>
	<brief_title>A New Tablet Containing Two FDA-Approved Drugs In HIV-Infected Patients Who Have Not Received Prior Therapy</brief_title>
	<detailed_description />
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Abacavir</mesh_term>
	<mesh_term>Efavirenz</mesh_term>
	<mesh_term>Lamivudine</mesh_term>
	<mesh_term>Tenofovir</mesh_term>
	<criteria>Inclusion criteria: Participants must be able to provide informed consent. Have documented HIV1 infection. Have not received more than 14 days of prior treatment with antiretroviral drugs. Meet laboratory test criteria. Women of childbearing potential must abstain from sexual intercourse or use acceptable contraception. Must be able to take study medications as directed and complete all study visits and evaluations during the 48 week study. Exclusion criteria: Enrolled in other HIV treatment studies. Pregnant or breastfeeding.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2010</verification_date>
	<keyword>HIV-1 Efavirenz Tenofovir</keyword>
</DOC>